Palladia: Product Information
PALLADIA- toceranib phosphate tablet
Zoetis Inc.
Antineoplastic For oral use in dogs only
Caution
Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
Description
PALLADIA, a multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK), is the phosphate salt of toceranib. The empirical formula is C22 H25 FN4 O2 H3 O4 P and the molecular weight is 494.46. The chemical name is (Z)-5-[(5-Fluoro-2-oxo-1,2-dihydro-3H -indol-3-ylidene)methyl]-2,4-dimethyl-N -(2-pyrrolidin-1-ylethyl)-1H -pyrrole-3-carboxamide phosphate. Toceranib phosphate is a small molecule with an indolinone chemical structure.
The chemical structure of toceranib phosphate is
Indications
PALLADIA tablets are indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs.
Dosage and Administration
Always provide Client Information Sheet with prescription. Administer an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day (see Table 1). Dose reductions of 0.5 mg/kg (to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day) and dose interruptions (cessation of PALLADIA for up to two weeks) may be utilized, if needed, to manage adverse reactions (see Table 2 as well as Warnings and Precautions). Adjust dose based on approximately weekly veterinary assessments for the first 6 weeks and approximately every 6 weeks, thereafter. PALLADIA may be administered with or without food. Do not split tablets.
| Dog Body Weight | Number of Tablets | ||||
|---|---|---|---|---|---|
| Pounds | Kilograms | Dose | 10 mg | 15 mg | 50 mg |
| 11.0 – 11.8 | 5.0 — 5.3 | 15 mg | 1 | ||
| 11.9 – 15.2 | 5.4 — 6.9 | 20 mg | 2 | ||
| 15.3 – 18.5 | 7.0 — 8.4 | 25 mg | 1 | 1 | |
| 18.6 – 22.0 | 8.5 — 10.0 | 30 mg | 2 | ||
| 22.1 – 25.4 | 10.1 — 11.5 | 35 mg | 2 | 1 | |
| 25.5 – 28.7 | 11.6 — 13.0 | 40 mg | 1 | 2 | |
| 28.8 – 32.2 | 13.1 — 14.6 | 45 mg | 3 | ||
| 32.3 – 35.5 | 14.7 — 16.1 | 50 mg | 1 | ||
| 35.6 – 38.8 | 16.2 — 17.6 | 55 mg | 1 | 3 | |
| 38.9 – 42.3 | 17.7 — 19.2 | 60 mg | 1 | 1 | |
| 42.4 – 45.6 | 19.3 — 20.7 | 65 mg | 1 | 1 | |
| 45.7 – 50.7 | 20.8 — 23.0 | 70 mg | 2 | 1 | |
| 50.8 – 59.3 | 23.1 — 26.9 | 80 mg | 2 | 1 | |
| 59.4 – 65.9 | 27.0 — 29.9 | 95 mg | 3 | 1 | |
| 66.0 – 71.2 | 30.0 — 32.3 | 100 mg | 2 | ||
| 71.3 – 76.3 | 32.4 — 34.6 | 110 mg | 1 | 2 | |
| 76.4 – 79.6 | 34.7 — 36.1 | 115 mg | 1 | 2 | |
| 79.7 – 84.7 | 36.2 — 38.4 | 120 mg | 2 | 2 | |
| 84.8 – 94.8 | 38.5 — 43.0 | 130 mg | 2 | 2 | |
| 94.9 – 105.0 | 43.1 — 47.6 | 150 mg | 3 | ||
| 105.1 – 110.0 | 47.7 — 49.9 | 160 mg | 1 | 3 | |
| 110.1 – 113.5 | 50.0 — 51.5 | 165 mg | 1 | 3 | |
| 113.6 – 118.6 | 51.6 — 53.8 | 170 mg | 2 | 3 | |
| 118.7 – 128.8 | 53.9 — 58.4 | 180 mg | 2 | 3 | |
| 128.9 – 138.9 | 58.5 — 63.0 | 200 mg | 4 | ||
| 139.0 – 144.0 | 63.1 — 65.3 | 210 mg | 1 | 4 | |
| 144.1 – 157.6 | 65.4 — 71.5 | 215 mg | 1 | 4 | |
| 157.7 – 173.1 | 71.6 — 78.5 | 250 mg | 5 | ||
| 173.2 – 177.9 | 78.6 — 80.7 | 260 mg | 1 | 5 | |
| 178.0 – 191.6 | 80.8 — 86.9 | 265 mg | 1 | 5 | |
| 191.7 – 220.5 | 87.0 — 100.0 | 300 mg | 6 | ||
| Toxicity | Dose Adjustment |
|---|---|
| Neutropenia | |
| >1000/µL | Maintain dose level |
| ≤1000/µL or neutropenic fever or infection | Stop drug until >1000/µL and clinical signs normal; then decrease dose by 0.5 mg/kg |
| Renal Toxicities (Creatinine) | |
| <2.0 mg/dL | Maintain dose level |
| ≥2.0 mg/dL | Stop drug until <2.0 mg/dL then decrease dose by 0.5 mg/kg |
| Albumin | |
| <1.5 g/dL | Stop drug until >2.5 g/dL then decrease dose by 0.5 mg/kg |
| Hematocrit | |
| <26% | Stop drug until >30% then decrease dose by 0.5 mg/kg |
| Diarrhea | |
| <4 watery stools/day for less than 2 days | Maintain dose level and institute supportive care |
| ≥4 watery stools/day or ≥ 2 days | Stop drug until formed stools and institute supportive care. When dosing is resumed, decrease dose by 0.5 mg/kg |
| GI Bleeding | |
| Fresh blood in stool or black tarry stool for > 2 days or frank hemorrhage or blood clots in stool. | Stop drug and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg/kg. |
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.